HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

491.015

-12.383-2.46%

Number of Gainers:6

Number of Losers:24

Number of Flat:3

PE:- -

High:505.901

Open:503.516

Low:489.953

Close:503.398

Volume:41.19M

Turnover:1.52B

Market Cap:313.71B

Float Cap:277.56B

Loading ...

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 21.78-22.2

Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses

Simply Wall St.

Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales

AH Premium Rankings for August 28: NE Electric Leads, CATL Records Negative Premium

Sweden's Elicera Therapeutics Q2 Loss Widens

InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn

Simply Wall St.

Fosun Chairman Guo Guangchang: Staying the Course on Core Sectors Like Pharma with R&D Spend of RMB 4.2 Billion in H1, Up 16.7%

Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint

Zhongjing Wanxi Pharma Donates One Million Yuan to Quake-Hit Gyirong in Tibet

Shares of TYK Medicines-B Jump Nearly 15% in Morning Trading as Its Innovative Drug TY-9591 Receives Conditional Market Approval

Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live

New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth

Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer

Simply Wall St.

CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million

HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management

HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year

Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":491.01474,"timestamp":1788233225510,"preClose":503.39795,"halted":0,"volume":41192153,"delay":0,"changeRate":-0.024599,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-12.383209,"latestTime":"09-01 11:27:05","open":503.51608,"high":505.9005,"low":489.95316,"amount":1522165169,"amplitude":0.031679,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1788235200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.001568,"increases":6,"decrements":24,"flats":2,"marketCap":313709414096,"floatMarketCap":277563004088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.031679,"preClose":503.39795,"low":489.95316,"pbRate":"3.790203","latestPrice":491.01474,"volume":41192153,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.001568,"peRate":127.340212,"marketCap":313709414096,"floatMarketCap":277563004088,"timestamp":1788233225510,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":24,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662060331","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return Reporting Share Repurchase at HKD 21.78-22.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060331","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662060331?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:50","pubTimestamp":1787917803,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return reporting share repurchase at HKD 21.78-22.2Zylox-Tonbridge filed an HKEX next-day disclosure return showing a repurchase of 53,000 H shares on Au","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLrVW9h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02190","BK1100","BK1587","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662935380","title":"Alphamab Oncology (SEHK:9966) Stock Rally Meets Revenue Dip And Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2662935380","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662935380?lang=en_us&edition=fundamental","pubTime":"2026-08-28 19:32","pubTimestamp":1787916728,"startTime":"0","endTime":"0","summary":"Alphamab Oncology stock has been on a short run higher, with the shares up about 15% over the past month. However, today’s earnings send a very different message. The headline is simple: revenue for the first half of 2026 came in at ¥271.2m, while the company reported a net loss of ¥40.5m and a basic loss per share of ¥0.04.\nFor a biotech that still trades on revenue potential more than profit, this contrast between top line and continuing losses is what the market is really reacting to. The...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-stock-rally-meets-revenue-dip-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FEBU","JOYT","VOTE","BK1161","09966","BK1574","GXDW","VGFPF","DECU","PMDE","RGLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163785274","title":"Goldman Sachs Lifts Innocare Price Target to HK$22.71 on Robust Orelabrutinib Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=1163785274","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163785274?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:40","pubTimestamp":1787906422,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research report raising its earnings per share forecasts for INNOCARE (09969) for the 2026 to 2028 period, from 0.15, 0.05, and 0.32 yuan to 0.16, 0.08, and 0.37 yuan,...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1144417596.USD","LU1894683264.USD","688428","LU0096364046.USD","09969","LU0106831901.USD","LU1804176565.USD","LU1868836757.USD","LU1894683348.USD","LU2237438978.USD","LU0742534661.SGD","LU0868494617.USD","LU0345770308.USD","BK1161","IE00B19Z3B42.SGD","LU2237443895.HKD","LU1868837300.USD","LU2237443978.SGD","LU2265009873.SGD","BK0239","IE00BFXG1179.USD","LU1791807156.HKD","GS","LU1868837136.USD","EWH","LU1868836914.USD","BK4127","BK4550","IE0034235188.USD","LU0868494708.USD","LU0345770993.USD","BK4588","LU2237443382.USD","LU0942090050.USD","LU2237443465.HKD","LU2237443622.USD","IE00BSNM7G36.USD","LU0251142724.SGD","LU2471134879.HKD","IE0004086264.USD","LU2471134796.USD","LU2750360997.AUD","BK1574","LU2237443549.SGD","BK4504","LU0210536198.USD","BK4533","LU2471134952.CNY","LU2896262040.SGD","IE0004091025.USD","LU0048573561.USD","GSX","BK4516","LU2471134523.USD","LU0061475181.USD","BK4552","LU0251131958.USD","LU2750360641.GBP","LU1868836591.USD","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137057087","title":"AH Premium Rankings for August 28: NE Electric Leads, CATL Records Negative Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=1137057087","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137057087?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:21","pubTimestamp":1787905307,"startTime":"0","endTime":"0","summary":"As of the close of trading on August 28, the latest A-H share premium data has been released, offering a comprehensive snapshot of the valuation gap between dual-listed stocks. The rankings highlight...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1190","BK1530","LU2394011477.USD","LU0821914370.USD","LU0516422440.USD","BK1193","LU0320764755.SGD","LU1244550494.USD","BK1144","BK1205","BK1514","LU0348825331.USD","IE00B5MMRT66.SGD","IE00BF5LJ272.USD","LU1675838814.USD","LU0082770016.SGD","LU1813983027.USD","LU2476274720.SGD","LU1251922891.USD","BK1505","LU1188198961.HKD","03308","LU0588546209.SGD","LU2177674079.SGD","BK1554","LU0672654166.SGD","LU0648948544.HKD","LU0165289439.USD","LU0791591158.USD","BK1231","LU0456827905.SGD","LU1688375341.USD","BK1546","HK0000352291.HKD","BK1507","LU0039217434.USD","LU0082770016.USD","BK1116","LU0329678337.USD","LU1655091616.SGD","HK0000352382.USD","LU0048580855.USD","LU0449509016.USD","LU0287142896.SGD","LU0307460666.USD","LU1328277881.USD","LU2476274308.USD","LU0327786744.USD","LU0862451753.SGD","06821","LU0708995583.HKD","LU1244550577.SGD","LU0244354667.USD","BK1198","02727","03908","LU1115378108.SGD","LU0231483743.USD","IE00BZ08YT58.USD","LU0329678170.USD","LU0516423091.SGD","LU1105468828.SGD","LU0054450605.USD","BK1594","LU0516423174.USD","HK0000252152.HKD","03750","LU0828237510.HKD","LU0029875118.USD","02359","LU0348766576.USD","LU0449515922.USD","BK1209","SG9999002463.SGD","LU1719994722.HKD","BK1583","IE00B3M56506.USD","HK0001040168.HKD","LU1282649810.SGD","SG9999001093.SGD","LU0106959298.USD","LU0043850808.USD","LU0890818403.SGD","LU0589944569.HKD","LU0516422366.SGD","LU1366334578.USD","IE0008368742.USD","LU0228367735.SGD","HK0000306685.HKD","LU0918141887.USD","BK1523","BK1506","LU0463099449.HKD","LU0049853897.USD","LU0181495838.USD","IE00B29SXG58.USD","BK1610","02338","BK1544","LU0149721374.USD","BK1562","LU0228659784.USD","LU0096374516.USD","LU0620787316.HKD","LU0266512127.USD","LU3063872942.SGD","LU0823426480.USD","BK1533","LU1961090484.USD","LU2045819591.USD","BK1105","LU0315179316.USD","IE00BVYPNQ40.USD","HK0000252160.HKD","SG9999006597.SGD","LU1224709979.USD","LU1152091754.HKD","LU0269904917.USD","03328","LU0531970944.HKD","BK1551","LU0456846285.SGD","LU0501845795.SGD","LU0320764599.SGD","BK1592","LU0828238088.HKD","LU1046422090.SGD","LU0531971595.HKD","LU0345780521.USD","LU1808992512.USD","LU0572944931.SGD","LU2097828631.EUR","LU0348805143.USD","BK1161","LU1282649141.HKD","LU1008478684.HKD","LU1152091168.USD","LU1988902786.USD","LU0370786039.SGD","03296","159982","00300","LU2242644610.SGD","BK1515","LU0359201885.HKD","LU0348814723.USD","LU0229945570.USD","LU1064131342.USD","BK1574","BK1564","BK1122","00991","BK1576","00981","LU2097828805.USD","BK1249","LU0540923850.HKD","00187","LU0886674414.USD","IE00BMCWC346.EUR","BK1141","LU0328353924.USD","LU0456854461.SGD","LU1831875114.USD","LU0051755006.USD","LU0640798160.USD","LU0214875030.USD","BK1501","IE00BYV24P56.USD","LU0254981946.USD","03200","LU0791590937.USD","LU2008162690.USD","LU0737861699.HKD","IE00B0169L03.USD","LU1481107354.HKD","LU0828237940.HKD","LU0543330566.HKD","LU0314109678.HKD","EWH","LU1769817096.USD","IE00B543WZ88.USD","BK1202","BK1522","LU0211977185.USD","IE0031814852.USD","LU0117841782.USD","00317","LU0163747925.USD","BK1614","LU0871576103.HKD","HK0000320264.USD","LU2097828474.EUR","02475","BK1149","00916","LU0868486357.SGD","LU1880383366.USD","LU2264538146.SGD","LU1242518857.USD","LU1720050803.USD","BK1526","LU0106252389.USD","82846","LU1023057109.AUD","IE0034224299.USD","LU1769817179.HKD","LU2125910500.SGD","IE00BGHQDM52.EUR","BK1191","02846","BK1183","03986","SG9999014674.SGD","LU2778985437.USD","HK0000500386.USD","LU0348827113.USD","LU0431992006.USD","01812","BK1558","BK1223","03678","HK0000306701.USD","LU2097828557.USD","LU1282649067.USD","83188","LU0067412154.USD","LU0797268264.HKD","LU0345780281.USD","LU0061477393.USD","IE0008369823.USD","06869","LU0266512473.USD","BK1516","HK0001040143.USD","01349","LU1303224171.USD","00638","LU0348767384.USD","83130","BK1560","02827","03130","LU2226246903.HKD","LU0072913022.USD","BK1147","LU2097828714.EUR","03143","LU0164939612.USD","LU0210526637.USD","01057","06185","LU1282648689.USD","LU0164880469.USD","BK1154","LU0052750758.USD","LU0348816934.USD","BK1125","SG9999004220.SGD","LU1226287529.USD","00568","LU0607220059.USD","399300","LU2399975544.HKD","LU1504937902.USD","LU1794554557.SGD","LU0516422952.EUR","LU0164865239.USD","IE00BZ08YR35.GBP","LU0543330483.HKD","LU0128522157.USD","03968","LU0348735423.USD","LU0979878070.USD","01033","LU0488056044.USD","LU1255011170.USD","LU0823040885.USD","02691","LU0326950275.SGD","SG9999002828.SGD","LU0348788117.USD","LU0509642566.USD","IE00B031J352.USD","LU1048596156.SGD","LU1993786604.SGD","01108","LU0359202008.SGD","02068","LU0417516902.SGD","LU0140636845.USD","BK1170","IE00BVYPNP33.GBP","LU0455707207.USD","LU0634319403.HKD","BK1214","BK1607","IE00BZ08YS42.EUR","01989","LU1244550221.USD","07233","LU1211504680.USD","LU0918141705.HKD","LU1770034418.SGD","LU0173614495.USD","LU0593848301.USD","IE00B031HY20.USD","03188","LU0384037296.USD","LU0149534421.HKD","LU0823426308.USD","IE0032431581.USD","LU0417516738.SGD","00553","00042","HK0000320223.HKD","LU1960683339.HKD","LU0561508036.HKD","LU0359201612.USD","LU1366334651.USD","BK1171","LU0469268626.HKD","SG9999011746.SGD","LU0502904849.HKD","BK1521","LU2294711473.HKD","LU2039709279.SGD","LU0880133367.SGD","LU1880383440.USD","BK1163","02899","LU0737861772.HKD","BK1148","LU1242518931.SGD","LU1807302812.USD","SG9999001226.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662513590","title":"Sweden's Elicera Therapeutics Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2662513590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662513590?lang=en_us&edition=fundamental","pubTime":"2026-08-28 14:12","pubTimestamp":1787897531,"startTime":"0","endTime":"0","summary":"Sweden's Elicera Therapeutics Q2 loss widensOverviewSweden CAR T-cell therapy developer's Q2 operating loss widened yr/yrLoss per share for Q2 increased to SEK -0.12 from SEK -0.06 yr/yrCompany raised","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P06L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LU1571399168.USD","BK4532","LU1868836591.USD","BK4007","LU1670710661.SGD","FTXH","LU1670710588.SGD","BK4581","LU0061475181.USD","LU0321505439.SGD","LU0882574055.USD","LU0225284248.USD","LU0432979614.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","LU0114720955.EUR","LU1074936037.SGD","LU1032466523.USD","BK4588","LU2133065610.SGD","LU2242652126.USD","BK1583","LU0321505868.SGD","LU0985481810.HKD","LU1868836914.USD","IHE","BK1161","BMY","IE00B2B36J28.USD","LU2125154935.USD","BK4585","LU1291159041.SGD","LU1983299246.USD","LU2242646821.SGD","LU2360032135.SGD","LU0096364046.USD","LU0306807586.USD","LU0267386448.USD","LU0306806265.USD","LU1883839398.USD","BK4559","IE00BSNM7G36.USD","02126","LU1670711123.USD","LU1868837300.USD","IE0009355771.USD","BK1574","LU1585245621.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063942","title":"InnoCare Pharma (SEHK:9969) Could Be 24% Undervalued Following Profit Turn","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063942","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662063942?lang=en_us&edition=fundamental","pubTime":"2026-08-28 13:16","pubTimestamp":1787894202,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SEHK:9969) stock is in focus after the company reported a shift from loss to profit in the first half of 2026 and issued guidance to remain profitable for the full year.\nThe recent earnings swing to profit and guidance for higher EPS in the second half appear to have supported InnoCare Pharma’s share price, which has a 90 day share price return of 27.52% and a year to date share price return of 18.64%, against a 1 year total shareholder return that is down 12.04%.\nCompare...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-could-be-24-undervalued-following-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-could-be-24-undervalued-following-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","09969","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150078686","title":"Fosun Chairman Guo Guangchang: Staying the Course on Core Sectors Like Pharma with R&D Spend of RMB 4.2 Billion in H1, Up 16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150078686","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150078686?lang=en_us&edition=fundamental","pubTime":"2026-08-28 13:11","pubTimestamp":1787893863,"startTime":"0","endTime":"0","summary":"During the 2026 interim results conference held in Hong Kong on August 28, FOSUN INTL Chairman Guo Guangchang stated that the company's first-half performance was impressive, confirming that the \"fix...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159982","BK1574","159938","00656","BK1515","BK1230","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662936058","title":"Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662936058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662936058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:45","pubTimestamp":1787885130,"startTime":"0","endTime":"0","summary":"Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpointAkeso highlighted late-stage gains for ivonescimab, with a Phase III first-line biliary tract cancer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL6VxC1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","LU0348735423.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","BK1574","LU2488822045.USD","BK1161","LU0540923850.HKD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516902.SGD","09926","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133942694","title":"Zhongjing Wanxi Pharma Donates One Million Yuan to Quake-Hit Gyirong in Tibet","url":"https://stock-news.laohu8.com/highlight/detail?id=1133942694","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133942694?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:03","pubTimestamp":1787882583,"startTime":"0","endTime":"0","summary":"On the morning of August 26, at around 10:30 AM, a debris flow triggered on the Nepalese side caused severe casualties and left people missing at the Gyirong Port in Gyirong County, Shigatse City,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156832241","title":"Shares of TYK Medicines-B Jump Nearly 15% in Morning Trading as Its Innovative Drug TY-9591 Receives Conditional Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1156832241","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156832241?lang=en_us&edition=fundamental","pubTime":"2026-08-28 09:41","pubTimestamp":1787881292,"startTime":"0","endTime":"0","summary":"TYK MEDICINES-B (02410) saw its shares surge nearly 15% in early trading, with the stock climbing 14.99% to HK$7.825 at the time of writing, on a turnover of HK$2.758 million.On the evening of August...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","IBBQ","06978","MEDX","02410","BK1161","09939","LNGR","159992","IPOS","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148206442","title":"Dizal Pharma Resubmits H-Share Listing Application to Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=1148206442","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148206442?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:28","pubTimestamp":1787876894,"startTime":"0","endTime":"0","summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced it resubmitted its application to list H-shares on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX) on August 27, 2026, with...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IPOS","159938","BK0239","BK1515","BK1161","09939","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203452","title":"Akeso's Losses Narrow in H1 as Revenue Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203452","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203452?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:06","pubTimestamp":1787875618,"startTime":"0","endTime":"0","summary":"Akeso  reported an attributable loss of 424.2 million yuan for the first half, narrowing from a loss of 570.1 million a year earlier.Loss per share stood at 0.46 yuan, compared with 0.64 yuan in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.The biotech company's revenue increased 28% year over year to 1.81 billion yuan for the six months ended June 30 from 1.41 billion yuan.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348766576.USD","LU1961090484.USD","BK1161","LU0417516738.SGD","LU2399975544.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU0348784397.USD","KURE","LU1720050803.USD","LU2778985437.USD","FCA","LU0348827113.USD","09926","LU2476274308.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU2476274720.SGD","LU0540923850.HKD","LU0348767384.USD","LU0634319403.HKD","BK1574","LU0348825331.USD","LU0348783233.USD","LU2488822045.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662103552","title":"New Zealand's Rua Bioscience FY Customer Revenue Jumps on Australia, NZ Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2662103552","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662103552?lang=en_us&edition=fundamental","pubTime":"2026-08-28 05:08","pubTimestamp":1787864935,"startTime":"0","endTime":"0","summary":"New Zealand's Rua Bioscience FY customer revenue jumps on Australia, NZ growthOverviewNew Zealand medicinal cannabis firm's preliminary FY26 customer revenue rose 71% yr/yr to NZ$2.58 mlnPreliminary F","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O18E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02616","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662033496","title":"Why Alphamab Oncology (SEHK:9966) Is Up 9.2% After Priority Review For Anbenitamab In HER2 Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2662033496","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662033496?lang=en_us&edition=fundamental","pubTime":"2026-08-28 03:29","pubTimestamp":1787858983,"startTime":"0","endTime":"0","summary":"Alphamab Oncology recently reported half-year 2026 results showing CNY 271.24 million in sales and a net loss of CNY 40.46 million, while also securing Chinese priority review for multiple Anbenitamab new drug applications in HER2-positive breast cancer.\nThe acceptance of these Anbenitamab applications, backed by a head-to-head phase III trial in advanced HER2-positive breast cancer, marks a rare case where a bispecific antibody combination outperformed the long-standing THP standard regimen...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/why-alphamab-oncology-sehk9966-is-up-92-after-priority-revie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662934081","title":"CStone Pharmaceuticals Posts HY Loss of Rmb252.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662934081","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662934081?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:55","pubTimestamp":1787846119,"startTime":"0","endTime":"0","summary":"BRIEF-CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 MillionAug 27 (Reuters)-CStone Pharmaceuticals2616.HK:HY LOSS RMB252.3 MILLIONHY REVENUE RMB205.1 MILLIONNO DIVIDENDS PAID, DECLARED OR PROPOSED DURING INTERIM PERIODFurther company coverage:2616.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0WN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662089078","title":"HBM Holdings Appoints Youchen Chen and Ian Yi Liu as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662089078","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662089078?lang=en_us&edition=fundamental","pubTime":"2026-08-27 23:34","pubTimestamp":1787844843,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Appoints Youchen Chen And Ian Yi Liu As Executive DirectorsAug 27 (Reuters)-Hbm Holdings Ltd2142.HK:APPOINTS YOUCHEN CHEN AND IAN YI LIU AS EXECUTIVE DIRECTORS EFFECTIVE AUGUST 27, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O1HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDXJ","LU1093756168.USD","BK4533","CDE","LU1721428933.USD","BK4567","LU0053666078.USD","BK4121","BK4107","02616","PFS","LU0210528500.USD","MTD","LU0347712357.USD","BK4585","LU1223082519.USD","IND","BK4017","SIL","XME","L","LU1093756325.SGD","LU2487616109.SGD","SGDM","LU2413666426.HKD","LU2211817866.USD","IE00B5TLWC47.USD","IE00BFXG0V08.USD","ORR","BK1574","BK4548","BK4588","BK1161","LU2413666699.HKD","BK4211","IE00BYQQ9H92.USD","BK4195","LU1223083913.SGD","LU1223082196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085572","title":"HBM Holdings Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085572","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085572?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:14","pubTimestamp":1787840073,"startTime":"0","endTime":"0","summary":"HBM Holdings files list of directors, board committee memberships and disclosure-responsible managementHBM Holdings set its board lineup as of Aug. 27, 2026, naming Dr. Jingsong Wang as chairman, chie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL4g9Z1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196427827","title":"HBM Holdings-B (02142) Posts First-Half Profit of $64.85M, Down 11.16% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1196427827","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196427827?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:14","pubTimestamp":1787840065,"startTime":"0","endTime":"0","summary":"HBM Holdings-B (02142) has announced its interim results for the six months ended June 30, 2026, reporting total revenue of $122 million, a 20.9% increase year-on-year. The company recorded a profit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085546","title":"Press Release: Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085546","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085546?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:09","pubTimestamp":1787839740,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the \"Company\"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and deve","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","TM","BK4099","BK1574","BK4585","BK4588","BK1583","BK4022","BK4604","03160","BK4232","BK4555","R"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":20,"pageCount":5,"totalSize":384,"code":"91000000","status":"200"}]}}